DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. While the company has achieved milestones, such as the first profitable year for IKC and strong international growth, challenges remain. The Q&A highlights concerns about ACA headwinds, missed treatments, and uncertainty in patient volume growth. Management's unclear responses to certain questions add to the uncertainty. Although there are positive elements, like reaffirmed guidance and strategic investments, the mixed financial outlook and external challenges suggest a neutral stock price movement in the short term.
Key Financial Performance
Revenue per treatment (RPT) Full year RPT was approximately $410, up 4.7% year-over-year. The increase was driven by normal rate increases, improved yield, a slight improvement in private pay mix, and the seasonal impact of flu vaccines.
Patient care cost per treatment (PCC) PCC per treatment increased by approximately $6 sequentially and finished the year 5.9% higher than 2024. The increase was primarily due to seasonal increases, including health benefit costs and higher supply costs. Approximately half of the year-over-year increase was from binders in the bundle.
Adjusted operating income (OI) Fourth quarter adjusted OI was $586 million, bringing full year adjusted OI to $2.094 billion. This reflects resilience despite challenges like a cyber incident. The IKC segment contributed positively with its first profitable year, delivering $22 million in full-year adjusted OI.
Adjusted earnings per share (EPS) Fourth quarter adjusted EPS from continuing operations was $3.40, with full year adjusted EPS at $10.78. This was achieved despite headwinds from a cyber incident and reflects strong operating performance.
Free cash flow Free cash flow was $309 million in the fourth quarter, bringing full year free cash flow to just over $1 billion. This reflects disciplined capital allocation and operational efficiency.
U.S. dialysis treatments Treatments declined by 1.1% year-over-year for the full year 2025, in line with expectations. The decline was attributed to elevated mortality and the timing of patient census gains.
International adjusted operating income Full year adjusted OI for the international segment was $114 million, reflecting strong organic growth and successful integration of acquisitions in Latin America.
Integrated Kidney Care (IKC) operating income IKC achieved its first profitable year in 2025, with full year adjusted OI of $22 million. This milestone was driven by sustainable contracts, physician partnerships, and a scalable care model supported by technology.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Integrated Kidney Care (IKC) programs: IKC patients achieve better outcomes, including 35% higher likelihood of starting dialysis with permanent vascular access, 3x lower costs in the first 180 days, fewer bloodstream infections, higher vaccination rates, and better treatment adherence. IKC achieved its first profitable year in 2025, ahead of schedule, and is expected to deliver $20 million incremental operating income growth in 2026.
Advancing dialysis technologies: Innovations like medium cutoff dialyzers and hemodiafiltration show promise in reducing mortality by 20% or more and improving patient recovery.
Strategic clinical partnership with Elara Caring: A partnership with Elara Caring was announced to establish an ESKD-focused offering, aiming to lower hospitalizations and missed treatment rates while improving patient experience.
International business growth: The international segment delivered positive organic growth and integrated recent acquisitions in Latin America, contributing $114 million in adjusted operating income for 2025.
Revenue per treatment (RPT): RPT grew by 4.7% in 2025, reaching approximately $410. Growth was driven by rate increases, improved private pay mix, and seasonal impacts like flu vaccines.
Cost management: Patient care costs per treatment increased by 5.9% in 2025, driven by seasonal and supply costs, but remained within revised expectations.
Focus on clinical excellence: Targeted initiatives include improving vaccination rates, GLP-1 adoption, and advancing dialysis technologies to enhance patient care and reduce mortality.
Capital allocation strategy: The company repurchased nearly 13 million shares in 2025 for $1.8 billion and plans further repurchases in 2026, alongside a $200 million minority investment in Elara Caring.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cyber Incident Impact: The U.S. dialysis business was negatively impacted by a cyber incident, which affected revenue and operations in 2025. Although the financial impact is expected to be eliminated in 2026, it highlights vulnerabilities in cybersecurity.
Elevated Mortality Rates: Continued pressure on treatment growth is driven by elevated mortality rates among patients, which poses a challenge to achieving higher treatment volumes.
Expiration of Enhanced Premium Tax Credits: The expiration of enhanced premium tax credits for exchange plans is expected to create a $40 million revenue headwind in 2026, impacting revenue per treatment.
Health Benefit Costs: Higher-than-expected health benefit costs were noted as a challenge in 2025, contributing to increased patient care costs per treatment.
Supply Chain Disruptions: Supply chain disruptions were mentioned as a challenge faced over the past five years, though specific ongoing impacts were not detailed.
Regulatory and Policy Changes: The business model and profitability of the Integrated Kidney Care (IKC) program are subject to changes in government policy, which could impact future operations and financial performance.
Competitive Dynamics: Competitive pressures in the healthcare sector, including innovations and partnerships by competitors, could impact DaVita's market position and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Adjusted Operating Income: Expected to range between $2.085 billion and $2.235 billion, representing 3.2% growth at the midpoint.
2026 Adjusted Earnings Per Share (EPS): Guided to a range of $13.60 to $15.00, reflecting a 33% growth at the midpoint.
2026 Free Cash Flow: Projected to be between $1 billion and $1.25 billion.
Integrated Kidney Care (IKC) Operating Income Growth: Expected to deliver an incremental $20 million of operating income growth in 2026.
Long-term Adjusted Operating Income Growth: Expected to grow consistently with a target of 3% to 7% over the next three years.
Long-term Adjusted EPS Growth: Projected to exceed the long-term guidance of 8% to 14% due to strong operating performance and capital allocation strategy.
U.S. Dialysis Treatment Volume: Forecasted to remain approximately flat in 2026 compared to 2025.
Revenue Per Treatment (RPT) Growth: Expected to grow by 1% to 2% in 2026.
U.S. Dialysis Costs: Anticipated to grow by 1.25% to 2.25% in 2026, driven by wage rate increases and G&A investments.
Elara Caring Investment: A $200 million minority investment expected to close midyear 2026, contributing positively to other income.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the fourth quarter, DaVita repurchased 2.7 million shares, and an additional 1.7 million shares were repurchased since the end of the quarter. For the full year 2025, nearly 13 million shares were repurchased for approximately $1.8 billion. A portion of these shares were repurchased from Berkshire Hathaway to maintain its ownership at or below 45%. The company plans to continue share repurchases in line with its typical framework, considering liquidity, leverage, and stock price relative to intrinsic value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives you confidence in achieving the 2% plus volume growth by 2026?
A:The confidence is based on clinical improvements, particularly in mortality rates. Historically, growth was driven by improving mortality rates year after year. The full effect of clinical implementations is expected by 2029, with some benefits visible in approximately 2 years.
Q:What is the time frame for the multiyear guidance ranges?
A:The guidance is thought of in a 3-year time frame.
Q:How should the $1.125 billion free cash flow number be interpreted in relation to the $200 million investment?
A:The $1.125 billion is before the $200 million investment. To calculate additional deployable capital, $200 million should be subtracted. Leverage levels should also be considered when determining share repurchases.
Q:How did missed treatments and mortality trend in the fourth quarter?
A:Missed treatments were up in Q4, which is typical for the quarter, but there was no significant year-over-year change compared to Q4 '24. There is a correlation between missed treatment rates and mortality, but with some lag.
Q:How will the ACA headwind play out this year, and how did open enrollment perform?
A:The ACA headwind is expected to be approximately $40 million this year, $70 million next year, and $10 million the year after. Open enrollment performed better than forecasted, but the real impact will depend on whether people pay for their plans. Patients are generally resilient in maintaining insurance due to their healthcare needs.
Q:How many ACA patients receive premium assistance?
A:The exact number is not known as it depends on various categories like enhanced premium tax credits and income levels.
Q:What is the impact of the cyber headwind and other reimbursement initiatives?
A:The $70 million cyber headwind includes $25 million in volume loss, which recurs, and $45 million in RPT headwind, which is offset by the enhanced premium tax credit headwind. There is no unusual resolution of older claims in 2025 compared to 2024.
Q:What drove the outperformance in IKC in 2024, and can it continue?
A:The outperformance was due to better shared savings from initiatives like medication management, transitions of care, and new interventions. The cumulative portfolio of efforts is working, and a $20 million improvement is expected for 2026.
Q:What is the impact of managing CKD patients and new drugs on disease progression and dialysis?
A:No significant shifts have been observed yet. The impact of new drugs takes time, and managing CKD populations is still in its early stages.
Q:What is the purpose of the Elara Caring investment?
A:The investment aims for good capital returns and to help the patient population by reducing hospitalizations, readmissions, and missed treatments through specialized kidney protocols.
Q:How should the international business be viewed in terms of growth and margins?
A:Growth is expected to be half M&A and half organic, with margins improving as fixed overhead is leveraged. The business contributes about 1 point to OI growth annually.
Q:Why is the rate of improvement in IKC slowing in 2026?
A:As the business matures and gets bigger, there is less opportunity to drive margins up. A $20 million annual improvement is considered a comfortable landing spot.
Q:What is the outlook for new starts in 2026 and their payer mix?
A:New starts are expected to remain flat, with a similar commercial mix as previous years, except for changes related to HICS.
Q:Was there a change in flu vaccination rates in Q4?
A:Vaccination rates are currently at 80%, down from a high in the 90s. Flu vaccines typically increase in Q4, impacting RPT and costs.
Q:What is the outlook for ESRD MA rates in 2027?
A:ESRD MA rates will receive a 6% increase in 2027, reflecting the reality of underfunding and encouraging MA plans to add these patients to their risk pool.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about how many ACA patients receive premium assistance, citing the complexity of categories and income levels. Additionally, the impact of managing CKD patients and new drugs on disease progression and dialysis was described as too early to tell, without providing specific data or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
COVID pneumonia
Capital Markets
Caring home
Day path
ESKD offering
GLP adoption
IKC basis
IKC caregiver
IKC health
IKC income
IKC model
IKC patient
IKC profitability
IKC program
IKC schedule
Innovations cutoff
Markets Day
adherence
benchmark
body
care patient
conference Group
confidence
dialysis IKC
evidence
focus
health care
life hospitalization
midpoint
model outcome
mortality treatment
patient dialysis
promise
quality life
technology
track record
vaccination rate
DVA Transcript
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
DaVita Inc. (DVA) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary shows modest growth in revenue, operating income, and net income, with improvements in free cash flow. However, the absence of strategic initiatives or operational updates, coupled with a lack of clarity in management's responses during the Q&A, suggests limited catalysts for significant stock movement. The overall sentiment is neutral as the financial performance is stable but not strong enough to drive a positive stock reaction, and there are no negative surprises to warrant a negative reaction.
DaVita Inc. (DVA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
Unknown2-2
The earnings call presents mixed signals. While the company has achieved milestones, such as the first profitable year for IKC and strong international growth, challenges remain. The Q&A highlights concerns about ACA headwinds, missed treatments, and uncertainty in patient volume growth. Management's unclear responses to certain questions add to the uncertainty. Although there are positive elements, like reaffirmed guidance and strategic investments, the mixed financial outlook and external challenges suggest a neutral stock price movement in the short term.
DVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
